Acute myeloid leukemia (AML) mainly affects children, with the prognosis often being poor despite several decades of research into more effective treatments. A new study led by researchers from the University of Basel and from Gustave Roussy Institute, Paris, explains why some forms of leukemia develop only in infants. The study also reveals potential new therapeutic targets, as the researchers report in the journal Cancer Discovery.
Over recent decades, research into pediatric cancer has intensified and treatments have improved, but the prognosis remains particularly unfavorable for young patients. Acute myeloid leukemia (AML) accounts for 15% of cases of leukemia diagnosed in children and adolescents. Overall survival at age five is around 60%, with relapse being the most common cause of mortality.
Abnormal protein fusion
There are several subtypes of AML. One of the most aggressive types, which is linked to treatment resistance and a particularly unfavorable prognosis, is acute megakaryoblastic leukemia (AML-M7).
It was on this particular form of leukemia that the research teams of Prof. Dr. Jürg Schwaller (University Children’s Hospital Basel and Department of Biomedicine at the University of Basel) and Prof. Dr. Thomas Mercher (INSERM U1170 at Gustave Roussy Institute, Université Paris Saclay) focused their attention.
In 2012, the research team around Mercher found that AML-M7 frequently presents genetic alterations that lead to the expression of an abnormal protein resulting from the fusion of the two proteins normally independent in the cell.
Although this fusion – known as ETO2-GLIS2 – has been identified in 30% of AML-M7 cases, the researchers had been unable to explain this abnormality. Similarly, it was unclear why children with AML-M7 are on average under age two while older children (on average towards the age of 6) are usually diagnosed with other pediatric AML subtypes.
To address these questions, the researchers developed a mouse model of AML-M7 to study the expression of ETO2-GLIS2 fusion. In this model, the researchers could first show that the activation of ETO2-GLIS2 fusion in fetal hematopoietic cells is sufficient to rapidly induce aggressive leukemia – which is very similar to AML-M7.
If, on the other hand, the fusion was activated in blood-forming cells of adult animals, this childhood leukemia did not occur, whereas other forms of AML developed much later. Moreover, by blocking ETO2-GLIS2 fusion in the in vivo model, researchers were able to bring tumor proliferation to a halt, with the abnormal blood cells once again able to differentiate into normal blood cells.
These findings suggest that this particular type of leukemia only occurs in infants because fetal hematopoietic cells – unlike adult ones – are more sensitive to certain genetic mutations such as ETO2-GLIS2 fusion. The study also shows that ETO2-GLIS2 fusion is the actual motor of this form of pediatric leukemia. The researchers will now try to directly inhibit the activity of this fusion in the tumor cells.
Prof. Dr. Jürg Schwaller, Department of Biomedicine, University of Basel and University Children’s Hospital Basel, phone +41 61 265 35 17, email: email@example.com
Cécile K. Lopez et al.
Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene-driven myeloid leukemia
Cancer Discovery (2019), doi: 10.1158/2159-8290.CD-18-1463
Iris Mickein | Universität Basel
Predicting a protein's behavior from its appearance
10.12.2019 | Ecole Polytechnique Fédérale de Lausanne
Could dark carbon be hiding the true scale of ocean 'dead zones'?
10.12.2019 | University of Plymouth
Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.
Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...
Using a clever technique that causes unruly crystals of iron selenide to snap into alignment, Rice University physicists have drawn a detailed map that reveals...
University of Texas and MIT researchers create virtual UAVs that can predict vehicle health, enable autonomous decision-making
In the not too distant future, we can expect to see our skies filled with unmanned aerial vehicles (UAVs) delivering packages, maybe even people, from location...
With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction
The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...
Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.
Fibroblasts kit - ready to heal wounds
03.12.2019 | Event News
15.11.2019 | Event News
15.11.2019 | Event News
10.12.2019 | Architecture and Construction
10.12.2019 | Information Technology
10.12.2019 | Life Sciences